title: Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study.
abstract: BACKGROUND
  The authors evaluated and compared the efficacy of 20 mg versus 40 mg of paroxetine in a randomized, double-blind, parallel-group study during a maintenance period of 28 months.
  
  
  METHODS
  Ninety-nine inpatients with recurrent, unipolar depression (DSM-IV criteria) who had at least 1 depressive episode during the 18 months preceding the index episode were openly treated with paroxetine 40 mg/day. Seventy-two subjects had a stable response (Hamilton Rating Scale for Depression score < 8) to paroxetine treatment and remained in the continuation treatment as outpatients for 4 months. At the time of recovery, 68 patients were randomly assigned to 1 of the 2 maintenance treatment groups: paroxetine 20 mg or paroxetine 40 mg daily.
  
  
  RESULTS
  Sixty-seven patients completed the 28-month follow-up period. Seventeen (51.5%) of 33 patients in the 20-mg paroxetine regimen had a single recurrence compared with 8 (23.5%) of 34 subjects in the 40-mg dose regimen (chi2 = 5.56, p = .018).
  
  
  CONCLUSIONS
  These data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes.
authors.affiliation: Istituto Scientifico H. San Raffaele, Department of Neuropsychiatric Sciences, School of Medicine, University of Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Franchini
authors.forename: M
authors.initials: M
authors.lastname: Gasperini
authors.forename: J
authors.initials: J
authors.lastname: Perez
authors.forename: E
authors.initials: E
authors.lastname: Smeraldi
authors.forename: R
authors.initials: R
authors.lastname: Zanardi
mesh_terms: D000328:Adult; D017668:Age of Onset; D000553:Ambulatory Care; D003866:Depressive Disorder / Q000188:drug therapy / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors